Pedro-antonio A. Regidor

Ismaning, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing® and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring.

Pharmacokinetic bioequivalence between (etonogestrel/ethinylestradiol 11.7/2.7 mg) NuvaRing® and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: August 17, 2026

Consensus statement of dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments.

Consensus statement of dienogest as a progestin in contraception and non-contraceptive clinical entities (heavy menstrual bleeding, acne and hirsutism). Narrative review of the literature and recent developments.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: July 08, 2026

Probiotic supplementation improves quality of life and modulates oestradiol in women with endometriosis: a randomised double-blind pilot trial.

Probiotic supplementation improves quality of life and modulates oestradiol in women with endometriosis: a randomised double-blind pilot trial.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: March 27, 2026

Comments on: 'Critical assessment of a prolonged-release EE/DNG contraceptive safety analysis' - a letter to the editor to the European Jornal of Contraception by Jonathan Douxfils et al.

Comments on: 'Critical assessment of a prolonged-release EE/DNG contraceptive safety analysis' - a letter to the editor to the European Jornal of Contraception by Jonathan Douxfils et al.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: February 17, 2026

Comment on Evaluation of the safety profile of prolonged-release EE/DNG oral contraceptives: a critical appraisal.

Comment on Evaluation of the safety profile of prolonged-release EE/DNG oral contraceptives: a critical appraisal.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Published: December 18, 2025

One-year clinical experience on the thromboembolic safety profile of the first prolonged release combined oral contraceptive containing 2 mg dienogest and 0.02 mg ethinyl-oestradiol.

One-year clinical experience on the thromboembolic safety profile of the first prolonged release combined oral contraceptive containing 2 mg dienogest and 0.02 mg ethinyl-oestradiol.

Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception

Published: December 02, 2025

Efficacy and acceptability of dienogest among patients with endometriosis in Thailand.

Efficacy and acceptability of dienogest among patients with endometriosis in Thailand.

Journal: BMC women's health

Published: September 30, 2025

Behavioral, antioxidant, and kynurenine pathway modulation of a specific strain of Ligilactobacillus salivarius in a preclinical model of depression.

Behavioral, antioxidant, and kynurenine pathway modulation of a specific strain of Ligilactobacillus salivarius in a preclinical model of depression.

Journal: European journal of nutrition

Published: July 04, 2025

Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial.

Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial.

Journal: EClinicalMedicine

Published: May 19, 2025

Narrative Review of Chronic Inflammation in Uterine Myoma: Lack of Specialized Pro-Resolving Lipid Mediators (SPMs) and Vitamin D as a Potential Reason for the Development of Uterine Fibroids.

Narrative Review of Chronic Inflammation in Uterine Myoma: Lack of Specialized Pro-Resolving Lipid Mediators (SPMs) and Vitamin D as a Potential Reason for the Development of Uterine Fibroids.

Journal: Biomedicines

Published: May 07, 2025

Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol.

Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol.

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Published: February 04, 2025

Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).

Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).

Journal: Biomedicines

Published: July 28, 2024

Showing 1-12 of 38

Last Updated: 09/26/2026